在莱布里奇祖马布治疗之外的缓解持续至38周,在亚托皮性皮炎中持续至38周
Jonathan I Silverberg1, Thomas Bieber2, Kilian Eyerich3
1George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
The Journal of dermatological treatment
|March 12, 2026
概括
对亚托皮炎 (AD) 的勒布里奇祖马布治疗显示,即使在停止使用药物后,皮肤也会持续改善. 一部分患者在停药38周以上的时间内保持显著反应.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 中度至重度的亚托皮性皮炎 (AD) 显著影响患者的生活质量.
- 莱布里基祖马布单一治疗已在成人和青少年治疗阿尔茨海默病方面表现出有效性.
- 了解治疗停止后反应的持续时间对于长期管理策略至关重要.
研究的目的:
- 评估血清lebrikizumab水平和治疗停止后持续的深度反应之间的关系.
- 确定在患有亚托皮性皮肤炎的患者中诱导后保持稳定的EASI 90响应的预测因素.
主要方法:
- 从两个3期随机,双盲,安慰剂对照试验 (ADvocate1和ADvocate2) 的综合分析.
- 包括第16周的响应者,他们被重新随机选择为安慰剂,并保持稳定的EASI 90响应直到第52周,没有救援药物.
- 血清lebrikizumab水平在4周,16周,32周和52周进行测量.
主要成果:
- 28%的患者 (17/60) 在没有救援药物的情况下,在停止治疗后至少38周内保持稳定的EASI 90反应.
- 从第16周到第32周,平均血清lebrikizumab水平下降了92%,到第52周下降了99%以上.
- 在戒断阶段观察到血清lebrikizumab水平的显著下降.
结论:
- 勒布里奇祖马布在亚托皮性皮肤炎患者的一个子组中证明了持续的治疗外维护反应.
- 这表明,即使在停止治疗后,疗效也可能延长.
- 进一步的研究可能会探索最佳的治疗持续时间和个性化的戒断策略.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
01:19Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
01:29Inflammatory Bowel Disease IV: Pharmacological Management
884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
884
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.2K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.2K